A venture capital firm with offices across Europe is investing from a EUR 120 million fund raised in 2019. The firm makes equity investments in early-to-late stage therapeutics, diagnostics, and medical devices companies. The firm can generally allocate between €2M to €10M. The firm only invests in companies that are based in Central and Western Europe. The firm is actively seeking new investment opportunities.

The firm is very opportunistic in the life sciences space. The firm focuses on therapeutics, diagnostics, and medical devices companies and is also interested in digital health. The firm targets therapeutic products in clinical trials or which are ready to enter Phase I, and medical devices which are CE Mark ready. The firm is very opportunistic in terms of subsectors and indications. However, the firm does not invest in cosmetics and dental devices. The firm strongly prefers companies developing products that address a highly unmet medical need. In digital health, the firm prefers to invest in products that have or are pursuing regulatory approval to monitor or treat a condition in which there is an unmet medical need. Generally these products will include both a hardware and a software component. The firm is not interested in consumer or lifestyle health products.

The firm plays the role of lead or co-lead investor in the large majority of its financing rounds. The firm requires a board seat in its portfolio companies. The firm seeks a company with a strong and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large US health system established an investment unit designed to achieve venture class returns through direct investments in innovative healthcare companies. In 2019 the firm closed a second $150 million venture and growth equity fund.  Typical equity allocations range from $8-15 million over the life of a company. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission to improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system. The firm is open to investing as a lead or co-investing along a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the USA invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies. The firm will generally lead investments and invests globally with no geographic restrictions.

The firm is agnostic across life science sectors, including therapeutics, devices and tools, but will not consider healthcare IT or digital health technologies. The firm focuses on discovery, early stage preclinical and clinical-stage opportunities, though may be open to commercial-stage or adjacent discovery/ development technologies.

The firm is seeking companies with founders who have a clear vision and desire to build a durable business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large biologics company headquartered in China with additional operations in USA and Asia, focuses on the development and commercialization of antibody-based therapeutics using advanced technologies. The company has a special focus on biosimilars and biobetters (mAbs and recombinant proteins) for malignant tumors (including solid tumor, lymphoma, etc.) and auto-immune diseases. Currently, the company’s pipeline covers over 8 biosimilars and 10 novel antibody products in pre-clinical and clinical development.

In addition to seeking out-licensing opportunities and strategic partnerships, the company is also seeking to in-license novel antibody product candidates in oncology that has synergies with the company’s current portfolio.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm established in early 2019 by a large network of hospitals, clinics, and home care services in the USA does direct, strategic investment in early-stage companies (with approximately half of this allocation dedicated to follow-on investments). The firm’s initial investments are usually in the range of $1-3M. The firm is geography agnostic and will consider all technologies across the globe.

The firm’s investments focuses on these 4 verticals: digital health, medical devices, healthcare technology systems, and healthcare services. The firm will not invest in biopharmaceuticals or in vitro diagnostics, though they may consider life science tools. In terms of medical devices, the firm prefers to invest in products who have achieved FDA approval, though the firm may consider and is open to speaking with earlier stage companies with strong fit. The firm expects technologies to have a strong alignment with the hospital network, and these technologies need to be useable and easily integrated with the health system. Practically, the firm expects to have a contract (or direct line of sight to a contract) at the time of investment. Some areas of particular interest include mental and behavioral health, postpartum care, interoperability among devices and health records, cognitive support for millennials, use of voice to diagnose and monitor health conditions, etc. Overall, the firm will take high interest in technologies that help deliver care outside of the hospital.

While the firm has no specific team requirements, the firm does like to see entrepreneurs and management teams with a strong tie to the product or market. To date, the firm has only done follow-on investments as part of a syndicate, but will be open to acting as lead investor in future opportunities, most likely starting from 2020 and beyond.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture/life science investment arm of a large Asia Pacific-based life science, and medical equipment manufacturer, invests from an evergreen fund and prefers to invest at company formation/seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of the parent corporate to help companies with regulatory affairs, market access, and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A London-based fund is focused on investing in advanced therapeutics. The firm invests both publicly and privately throughout the US, and Europe. For private deals, the firm makes equity deals in early-stage biotech therapeutic companies. The firm typically looks to make 8-10 deals in the private sector through each yearly cycle and typically allocates between $1M – $5M in each deal. The firm typically follows on these investments, preferring not to lead. The firm typically invests in seed and Series A rounds.

The firm is currently seeking biotech therapeutics that are considered advanced therapeutics. Examples of some therapies that the firm considers as advanced therapies are cell therapies and gene therapies. Currently, the firm is interested in immuno-oncology therapeutics, but is not interested in checkpoint inhibitors. For these therapeutics companies, they prefer that the asset is currently pre-clinical, in Phase I, or ready for phase II. The firm is agnostic in terms of specific indications.

The firm focuses on investing in companies located in the European Union, but typically finds that a good amount of their deals are based in the United States. The firm is open to other geographies, but has yet to see a deal that is particularly interesting to them from other areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.